Please assess the completion status of the following clinical trial:

Trial Title: SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Above 18 years of age~* Have positive SARS-CoV-2 PCR on nasopharyngeal and/or oropharyngeal swabs~* Admitted in isolation ward and ICU of institutes affiliated with DUHS~* have severe or critical COVID 19 as judged by the treating physician~* Consent given by the patient or first degree relative~Exclusion Criteria:~* Pregnancy~* Previous allergic reaction to immunoglobulin treatment~* Ig A deficiency~* Patient requiring 2 inotropic agents to maintain blood pressures~* Known case of any autoimmune disorder~* Acute kidney injury or chronic renal failure~* Known case of thromboembolic disorder~* Aseptic meningitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard care only n = 10 patients.
- IVIG dose: 0.15 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients
- IVIG dose: 0.20 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
- IVIG dose: 0.25 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
- IVIG dose: 0.30 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients

Based on this trial design, predict the completion outcome and termination type (if applicable).